48. Primary antiphospholipid syndrome Clinical trials / Disease details

Clinical trials : 5 / Drugs : 6 - (DrugBank : 4) / Drug target gene : 1 - Drug target pathways : 7

1 trial found

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05671757 (ClinicalTrials.gov)	March 12, 2023	20/12/2022	Daratumumab in Primary Antiphospholipid Syndrome	Targeting CD38 With Daratumumabin Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safe ...	Autoimmune Disorders	Biological: Daratumumab	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN);PPD;Rho Federal Systems Division, Inc.	Not yet recruiting	18 Years	65 Years	All	22	Phase 1/Phase 2	United States

First Previous1Next Last